Regeneron entered radiopharmaceutical expansion through a $2.1 billion biobucks pact with Telix. The agreement ties into Regeneron’s shifting growth strategy as its obesity program activity and pipeline evolution support a broader push into radiopharma. Radiopharmaceutical deals often reflect both manufacturing-readiness and clinical development capability, and Telix’s platform is positioned to accelerate theranostics and targeted radiation approaches. For Regeneron, the move increases portfolio diversification beyond antibody-centric or small-molecule-only growth engines. The next milestones likely include integration plans, clinical program selection, and whether the partnership emphasizes near-term development or longer-horizon platform building.